Key clinical point: Triple therapy with an inhaled corticosteroid is helpful for patients with chronic obstructive pulmonary disease who have high baseline eosinophil counts.
Major finding: For patients with baseline blood eosinophil counts of at least 310 cells per mcL, triple therapy with an inhaled corticosteroid was associated with about half as many moderate and severe exacerbations as dual therapy without a steroid (rate ratio = 0.56).
Study details: IMPACT was a double-blind, randomized, phase 3 trial involving 10,333 patients with moderate to very severe COPD.
Disclosures: The study was funded by GlaxoSmithKline. The investigators disclosed additional relationships with AstraZeneca, Boehringer Ingelheim, Chiesi, CSA Medical, and others.
Pascoe S et al. Lancet Resp Med. 2019 Jul 4. doi: 10.1016/S2213-2600(19)30190-0.